


Nemiralisib

Cat. No.:	HY-19535A		
CAS No.:	1254036-71-9		
Molecular Formula:	C ₂₆ H ₂₈ N ₆ O		
Molecular Weight:	440.54		
Target:	PI3K		
Pathway:	PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (75.66 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.2699 mL	11.3497 mL	22.6994 mL
		5 mM	0.4540 mL	2.2699 mL	4.5399 mL
10 mM		0.2270 mL	1.1350 mL	2.2699 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.25 mg/mL (5.11 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.25 mg/mL (5.11 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Nemiralisib (GSK2269557 free base) is a potent and highly selective PI3Kδ inhibitor with a pK _i of 9.9.			
IC ₅₀ & Target	PI3Kδ 9.9 (pKi)	PI3Kγ 5.2 (pIC ₅₀)	PI3Kα 5.3 (pIC ₅₀)	PI3Kβ 5.8 (pIC ₅₀)
In Vitro	<p>Nemiralisib (GSK2269557 free base) is highly selective for PI3Kδ, with >1000-fold selectivity over the closely related isoforms PI3Kα (pIC₅₀=5.3), PI3Kβ (pIC₅₀=5.8) and PI3Kγ (pIC₅₀=5.2). Nemiralisib inhibits IFNγ in the peripheral blood mononuclear (PBMC) assay with an pIC₅₀ of 9.7^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>			

In Vivo

To assess the suitability of the series for inhaled delivery clearance data in rat microsomes and subsequently in vivo pharmacokinetic data from Sprague Dawley male rats is obtained. Compounds (e.g., Nemiralisib) are administered by the oral or intravenous routes, at a dose level of 3 and 1mg/kg respectively (n=2 rats/route). Nemiralisib free base is active in a disease relevant brown norway rat acute OVA model of Type 2 helper T-cells (Th2)-driven lung inflammation^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]

Rats^[1]

In vivo pharmacokinetics is tested in Sprague Dawley male rats. Compounds (e.g., Nemiralisib) are administered discretely by the oral or intravenous routes, at a dose level of 3 and 1 mg/kg respectively (n=2 rats/route). Compounds (e.g., Nemiralisib) are formulated as a solution in DMSO:PEG200:water (5:45:50 v/v/v) at a dose volume of 6 (oral) and 2 (intravenous) mL/kg. All animals are serially bled from the tail vein and blood samples collected over a time-course of 0-7 h are submitted to LC-MS/MS analysis for the quantification of the parent compound. The main pharmacokinetic parameters are estimated by non-compartmental analysis.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Down K et al. Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease. *J Med Chem.* 2015 Sep 24;58(18):7381-99.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA